Elgan Pharma Ltd.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

ELGN-2112 · Diabetes
ELGN-2112 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Elgan Pharma Ltd. portfolio CI brief
Elgan Pharma Ltd. pipeline updates RSS

Frequently asked questions about Elgan Pharma Ltd.

What is Elgan Pharma Ltd.'s pipeline?

Elgan Pharma Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include ELGN-2112.

Sector hub: All tracked pharma companies